Spondyloarthritis Research and Treatment Network (SPARTAN) Clinical and Imaging Year in Review 2024.

IF 5.7 2区医学 Q1 RHEUMATOLOGY

Current Rheumatology Reports Pub Date : 2025-07-01 DOI:10.1007/s11926-025-01195-8

Renato Ferrandiz-Espadin, Jean W Liew

{"title":"Spondyloarthritis Research and Treatment Network (SPARTAN) Clinical and Imaging Year in Review 2024.","authors":"Renato Ferrandiz-Espadin, Jean W Liew","doi":"10.1007/s11926-025-01195-8","DOIUrl":null,"url":null,"abstract":"Purpose of review: Diagnostic delay remains a critical challenge in axial spondyloarthritis (axSpA). This review highlights key clinical and imaging research from 2024 that addresses this persistent issue, with a focus on the evolving roles of MRI, artificial intelligence (AI), and updated Canadian management recommendations.Recent findings: Multiple studies published in 2024 emphasized the continued problem of diagnostic delay in axSpA. Studies support the continued use of sacroiliac joint MRI as a central diagnostic tool for axSpA, particularly in patients with chronic back pain and associated conditions like uveitis, psoriasis (PsO), or inflammatory bowel disease. AI-based tools for interpreting sacroiliac joint MRIs demonstrated moderate agreement with expert assessments, offering a potential solution to variability and limited access to expert musculoskeletal radiology. These innovations may support earlier diagnosis and reduce misclassification. Innovative models of care, including patient-initiated telemedicine visits, reduced in-person visit frequency without compromising clinical outcomes in patients with stable axSpA. Updated Canadian treatment guidelines introduced more robust data on Janus kinase (JAK) inhibitors and offered stronger support for tapering biologics in patients with sustained low disease activity or remission, while advising against abrupt discontinuation. This clinical and imaging year in review covers challenges and innovations in axSpA, emphasizing the need for early access to care and the development of tools to support prompt diagnosis and sustained continuity of care.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"27 1","pages":"29"},"PeriodicalIF":5.7000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Rheumatology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11926-025-01195-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Diagnostic delay remains a critical challenge in axial spondyloarthritis (axSpA). This review highlights key clinical and imaging research from 2024 that addresses this persistent issue, with a focus on the evolving roles of MRI, artificial intelligence (AI), and updated Canadian management recommendations.

Recent findings: Multiple studies published in 2024 emphasized the continued problem of diagnostic delay in axSpA. Studies support the continued use of sacroiliac joint MRI as a central diagnostic tool for axSpA, particularly in patients with chronic back pain and associated conditions like uveitis, psoriasis (PsO), or inflammatory bowel disease. AI-based tools for interpreting sacroiliac joint MRIs demonstrated moderate agreement with expert assessments, offering a potential solution to variability and limited access to expert musculoskeletal radiology. These innovations may support earlier diagnosis and reduce misclassification. Innovative models of care, including patient-initiated telemedicine visits, reduced in-person visit frequency without compromising clinical outcomes in patients with stable axSpA. Updated Canadian treatment guidelines introduced more robust data on Janus kinase (JAK) inhibitors and offered stronger support for tapering biologics in patients with sustained low disease activity or remission, while advising against abrupt discontinuation. This clinical and imaging year in review covers challenges and innovations in axSpA, emphasizing the need for early access to care and the development of tools to support prompt diagnosis and sustained continuity of care.

查看原文本刊更多论文

脊柱关节炎研究和治疗网络（SPARTAN）临床和影像学回顾2024年。

回顾目的：诊断延迟仍然是轴性脊柱炎（axSpA）的一个关键挑战。本综述重点介绍了2024年以来解决这一持续问题的关键临床和影像学研究，重点介绍了MRI、人工智能（AI）的演变作用，以及最新的加拿大管理建议。最新发现：2024年发表的多项研究强调了axSpA诊断延迟的持续问题。研究支持继续使用骶髂关节MRI作为axSpA的中心诊断工具，特别是对于慢性背痛和相关疾病如葡萄膜炎、牛皮癣（PsO）或炎症性肠病的患者。用于解释骶髂关节mri的基于人工智能的工具显示出与专家评估的适度一致，为变异性和有限的专家肌肉骨骼放射学提供了潜在的解决方案。这些创新可能有助于早期诊断并减少误分类。创新的护理模式，包括患者发起的远程医疗就诊，在不影响稳定axSpA患者临床结果的情况下减少了亲自就诊频率。更新后的加拿大治疗指南引入了更多关于Janus激酶（JAK）抑制剂的可靠数据，并为持续低疾病活动度或缓解的患者减量使用生物制剂提供了更强有力的支持，同时建议不要突然停药。本年度临床和影像学回顾涵盖了axSpA面临的挑战和创新，强调需要尽早获得护理和开发工具，以支持及时诊断和持续持续的护理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Rheumatology Reports RHEUMATOLOGY-

CiteScore

11.20

自引率

0.00%

发文量

期刊介绍： This journal aims to review the most important, recently published research in the field of rheumatology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care and prevention of rheumatologic conditions. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas such as the many forms of arthritis, osteoporosis and metabolic bone disease, and systemic lupus erythematosus. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also occasionally provided.